BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7831670)

  • 1. The calcium modulator nifedipine exerts its antiaggregatory property via a nitric oxide mediated process.
    Berkels R; Klaus W; Boller M; Rösen R
    Thromb Haemost; 1994 Aug; 72(2):309-12. PubMed ID: 7831670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relaxin depresses platelet aggregation: in vitro studies on isolated human and rabbit platelets.
    Bani D; Bigazzi M; Masini E; Bani G; Sacchi TB
    Lab Invest; 1995 Nov; 73(5):709-16. PubMed ID: 7474945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the importance of the proposed release of nitric oxide from platelets.
    Mollace V; Salvemini D; Vane J
    Thromb Res; 1991 Dec; 64(5):533-42. PubMed ID: 1725563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effects of endogenous L-arginine analogues on nitric oxide synthesis in platelets: role in platelet hyperaggregability in hypertension.
    de Meirelles LR; Mendes-Ribeiro AC; Santoro MM; Mendes MA; da Silva MN; Mann GE; Brunini TM
    Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1267-71. PubMed ID: 17973865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature.
    Emerson M; Momi S; Paul W; Alberti PF; Page C; Gresele P
    Thromb Haemost; 1999 Jun; 81(6):961-6. PubMed ID: 10404776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial cells play an important role in the antiaggregatory effect of nitric oxide.
    Klinge JM; Topf HG; Trusen B; Rauh M; Rascher W; Dötsch J
    Crit Care Med; 2003 Jul; 31(7):2010-4. PubMed ID: 12847397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
    Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
    Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet effect of amlodipine: a possible mechanism through a nitric oxide-mediated process.
    Chou TC; Li CY; Yen MH; Ding YA
    Biochem Pharmacol; 1999 Nov; 58(10):1657-63. PubMed ID: 10535758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential actions of naftopidil, doxazosin and nifedipine on platelet thromboxane generation and platelet-derived growth factor efflux in vitro.
    Alarayyed NA; Prichard BN; Betteridge DJ; Smith CC
    Platelets; 2002; 13(5-6):267-71. PubMed ID: 12189011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct electrochemical measurement of nitric oxide released from human platelets.
    Malinski T; Radomski MW; Taha Z; Moncada S
    Biochem Biophys Res Commun; 1993 Jul; 194(2):960-5. PubMed ID: 8343175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of platelet aggregation by diltiazem. Comparison with verapamil and nifedipine and inhibitory potencies of diltiazem metabolites.
    Kiyomoto A; Sasaki Y; Odawara A; Morita T
    Circ Res; 1983 Feb; 52(2 Pt 2):I115-9. PubMed ID: 6831645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of L-arginine load on platelet aggregation: a comparison between normotensive and preeclamptic pregnant women.
    Facchinetti F; Neri I; Piccinini F; Marietta M; Torelli U; Bruschettini PL; Volpe A
    Acta Obstet Gynecol Scand; 1999 Jul; 78(6):515-9. PubMed ID: 10376861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine.
    Alarayyed NA; Cooper MB; Prichard BN; Betteridge DJ; Smith CC
    Br J Clin Pharmacol; 1997 Apr; 43(4):415-20. PubMed ID: 9146854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide and prostacyclin modulate the alterations in cardiac action potential duration mediated by platelets during ischaemia.
    Goulielmos NV; Enayat ZE; Sheridan DJ; Cohen H; Flores NA
    Cardiovasc Res; 1995 Nov; 30(5):788-98. PubMed ID: 8595628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amifostine, a reactive oxigen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF.
    Porta C; Maiolo A; Tua A; Grignani G
    Haematologica; 2000 Aug; 85(8):820-5. PubMed ID: 10942928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin.
    Chakraborty K; Khan GA; Banerjee P; Ray U; Sinha AK
    Platelets; 2003; 14(7-8):421-7. PubMed ID: 14713511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide and platelet energy metabolism.
    Tomasiak M; Stelmach H; Rusak T; Wysocka J
    Acta Biochim Pol; 2004; 51(3):789-803. PubMed ID: 15448739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of antiplatelet effects of two nitric oxide-donating agents, FR146801 and FK409.
    Hirasawa Y; Kato Y; Fukuyama S; Ohno M; Nishino S; Kato M; Kita Y
    Thromb Haemost; 1998 Mar; 79(3):620-4. PubMed ID: 9531052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of antiplatelet activity of nifedipine: role of peroxisome proliferator-activated receptor-β-γ-dependent processes.
    Shih CY; Lin MH; Fan HC; Chen FC; Chou TC
    J Hypertens; 2014 Jan; 32(1):181-92. PubMed ID: 24126710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.